Behavioral Processes Underlying Reward Processing in Depression
NCT ID: NCT00205933
Last Updated: 2007-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
78 participants
OBSERVATIONAL
2004-04-30
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Right-handed
* DSM-IV diagnosis of MDD
* Score of at least 17 on the 21-item HAM-D scale
* Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
* No current or past history of MDD with psychotic features
* Absence of any other Axis I or Axis II diagnosis (Including bipolar disorder and current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded, since dopaminergic alterations have been reported in these conditions. Exclusion of patients with comorbid Axis I or Axis II diagnoses will be necessary as evidence exists of alteration in dopamine receptor density in detached personality and social phobia. The alteration of dopamine in the brain may in turn alter behavior.
* Absence of significant medical conditions
* Absence of ECT in the previous 6 months
* Ability to provide informed consent/authorization
Bipolar participants:
* Both genders and all ethnic origins
* Age between 18 and 64
* Right-handed
* DSM-IV diagnosis of Bipolar Disorder I or II
* Score of at least 17 on the 21-item Hamilton Depression Rating Scale (HAM-D)
* Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
* No current or past history of MDD with psychotic features
* Absence of any other Axis I or Axis II diagnosis (Including current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded.
* Absence of significant medical conditions
* Absence of ECT in the previous 6 months
* Ability to provide informed consent/authorization
Control Participants:
* Right-handed
* Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by the SCID
* Absence of any medications for at least 2 weeks
* Informed consent/authorization
Exclusion Criteria
* Evidence of neurological illness
* Current alcohol or substance abuse
* Serious suicide or homicide risk
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Affective Neuroscience Laboratory
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Harvard University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diego A Pizzagalli, PhD
Role: PRINCIPAL_INVESTIGATOR
Harvard University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Depression Clinical and Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States
Affective Neuroscience Laboratory, Department of Psychology, Harvard University
Cambridge, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2003-P-000994
Identifier Type: -
Identifier Source: org_study_id